Publications by authors named "Madeleine G Fish"
Purpose: Detection of persistent circulating tumor DNA (ctDNA) after curative-intent surgery can identify patients with minimal residual disease (MRD) who will ultimately recur. Most ctDNA MRD assays require tumor sequencing to identify tumor-derived mutations to facilitate ctDNA detection, requiring tumor and blood. We evaluated a plasma-only ctDNA assay integrating genomic and epigenomic cancer signatures to enable tumor-uninformed MRD detection.
View Article and Find Full Text PDFBackground: Survival in patients with metastatic colorectal cancer (mCRC) has been associated with tumor mutational status, muscle loss, and weight loss. We sought to explore the combined effects of these variables on overall survival.
Materials And Methods: We performed an observational cohort study, prospectively enrolling patients receiving chemotherapy for mCRC.
Article Synopsis
- Patient-reported outcomes (PROs) like quality of life (QOL) and symptom burden are linked to the clinical outcomes in cancer patients, but their relationship with treatment response is not well-studied.
- A study involving 112 patients with advanced gastrointestinal cancer found that higher physical symptom scores and lower functional QOL scores were associated with poorer treatment responses and increased hospitalization risks.
- The analysis indicates that baseline PROs can help predict treatment outcomes, healthcare utilization, and survival in these patients, emphasizing the importance of assessing physical symptoms and functional well-being.
Purpose: ctDNA offers a promising, noninvasive approach to monitor therapeutic efficacy in real-time. We explored whether the quantitative percent change in ctDNA early after therapy initiation can predict treatment response and progression-free survival (PFS) in patients with metastatic gastrointestinal cancer.
Experimental Design: A total of 138 patients with metastatic gastrointestinal cancers and tumor profiling by next-generation sequencing had serial blood draws pretreatment and at scheduled intervals during therapy.